Every one of those 1 sits in a single category, market-trends. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ACP-101
Every one of those 1 sits in a single category, market-trends. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.7. We currently track 1 Healthcare story that mention ACP-101, all published on February 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ACP-101. Shared-story counts are live from our verified record — not editorial picks.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.